Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials

[1]  S. Russell,et al.  Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study , 2018, Rheumatology.

[2]  D. Jevsevar,et al.  Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain , 2018, The Journal of bone and joint surgery. American volume.

[3]  F. Berenbaum,et al.  Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis , 2017, Arthritis & rheumatology.

[4]  L. Arendt-Nielsen,et al.  Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical pain , 2017, Scandinavian journal of rheumatology.

[5]  Xin-long Ma,et al.  Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: A meta-analysis. , 2017, International journal of surgery.

[6]  M. Cross,et al.  Osteoarthritis: A Serious Disease: Submitted to the U.S. Food and Drug Administration , 2016 .

[7]  A. Rutjes,et al.  Intra-articular corticosteroid for knee osteoarthritis. , 2015, The Cochrane database of systematic reviews.

[8]  D. Hunter,et al.  An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. , 2015, The Journal of bone and joint surgery. American volume.

[9]  S Lohmander,et al.  OARSI guidelines for the non-surgical management of knee osteoarthritis. , 2014, Osteoarthritis and cartilage.

[10]  X. Y. Zhang,et al.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials , 2013, BDJ.

[11]  C. Inderjeeth,et al.  FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis , 2013 .

[12]  Gordon Guyatt,et al.  American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee , 2012, Arthritis care & research.

[13]  P. Hayes,et al.  Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. , 2012, British journal of clinical pharmacology.

[14]  F. Berenbaum,et al.  A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis , 2012, Annals of the rheumatic diseases.

[15]  H. Zeidler.  Paracetamol and the Placebo Effect in Osteoarthritis Trials: A Missing Link? , 2011, Pain research and treatment.

[16]  F. Berenbaum,et al.  Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. , 2011, Clinical and experimental rheumatology.

[17]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[18]  D. Bloch,et al.  A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). , 2009, Seminars in arthritis and rheumatism.

[19]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[20]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[21]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[22]  H. Möllmann,et al.  Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra‐articular administration , 1986, Clinical pharmacology and therapeutics.

[23]  J. Kellgren,et al.  Radiological Assessment of Osteo-Arthrosis , 1957, Annals of the rheumatic diseases.

[24]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[25]  P. Conaghan,et al.  Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). , 2018, Osteoarthritis and cartilage.

[26]  A. Naranjo,et al.  A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project , 2011, Annals of the Rheumatic Diseases.